BRAF and melanoma: Considering that NRAS mutations are frequently reported as resistance mechanisms in BRAF-mutated melanomas treated with BRAF inhibitors [9,10,29], we investigated the effects of vemurafenib on melanoma cells harboring the NRASQ61R mutation.